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ABSTRACT
INTRODUCTION: Diabetes has risen to one of the top American public health concerns. The
hyperglycemic state of chronic diabetes leads to microvascular and macrovascular changes that predispose
patients to delayed wound healing and organ fibrosis. The validation of models to specifically detect early,
quantifiable fibrotic changes seen in the diabetic state is of fundamental importance for understanding the
diabetic pathophysiology and exploring earlier management options. Here, we investigated if we could
detect early signs of internal fibrosis in a streptozotocin (STZ) diabetic mouse model by quantifying
α-SMA expression in various organs using flow cytometry.
METHODS: We used a low-dose STZ-induced T1DM model. T1DM was confirmed via sustained
hyperglycemia (>250mg/dl) over 8-10 weeks. Delayed healing of full thickness wounds was confirmed by
tracking wound healing progression over two weeks. Wounded and unwounded skin samples were
analyzed histologically to quantify collagen deposition as a sign of fibrosis. Organ fibrosis was assessed in
a semi-high-throughput manner using flow cytometry to quantify the percentage of alpha-Smooth Muscle
Actin (α-SMA) positive cells in diabetic versus normoglycemic controls.
RESULTS: Combining STZ with post-injection glucose treatment yielded highly efficient 100%
pathogenesis with 100% survival. Diabetic mice showed signs of hyperglycemia, polyuria, and delayed
wound healing. Histological analysis indicated a greater increase in epidermal height and lower levels of
collagen deposition in diabetic wounds. After 10-12 weeks of hyperglycemia, we observed elevated
α-SMA in brain and retinal tissues.
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DISCUSSION: The STZ model has previously presented cumbersome, costly, and time-intensive
limitations for the study of diabetic complications. Here we tested a quantitative method for detecting
early signs of fibrosis using flow cytometry. The higher percentage of α-SMA positive cells in retinal and
brain tissue of diabetic mice suggests fibrosis of these tissues. We argue that this is a suitable method to
study early diabetic complications.
Keywords: diabetes, hyperglycemia, fibrosis, murine

INTRODUCTION

Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM) have risen to one of the top
American public health concerns, with a combined estimated prevalence rate of 11% (30.3 million cases)
in 20151,2. These numbers are predicted to rise by over 50% by 20301. Although the prevalence rate of
T1DM is highest among Caucasian populations, the steepest rise in incidence between 2000-2010 was
seen in pediatric Hispanic populations1−5. Prevalence and incidence of T2DM are highest among
non-Hispanic black populations3,4. Lower income levels and academic backgrounds are associated with
higher diabetes prevalence and disease-related complications6−9. There is a growing need to lower the
disease burden for these vulnerable populations.
Diabetes is a metabolic disorder caused by a functional insulin deficit, leading to an inability to properly
absorb glucose10. T1DM accounts for 10% of diabetic cases. It is caused by the T-cell mediated
autoimmune destruction of pancreatic islet β-cells, initiated by genetic mutation, viral infection, or
environmental factors. Loss of β-cells depletes the endogenous insulin supply. T1DM is associated with
autoimmune thyroid disease, celiac disease, autoimmune gastritis and Addison’s disease11. T2DM is an
acquired disorder caused by insulin resistance due to either polygenetic inheritance or metabolic overload
brought on by obesity or sedentary lifestyle. Because some insulin activity is maintained, T2DM is
generally a milder disease than T1DM. T2DM is associated with hypertension, dyslipidemia, metabolic
syndrome, or polycystic ovarian syndrome.
In both T1DM and T2DM, hyperglycemia increases osmolarity and oxidative stress. This leads to
neuropathies that impair peripheral sensation, motor control, and autonomics. Loss of functional insulin,
which normally acts as a weak vasodilator, leads to increased vasoconstriction, peripheral vascular disease
(PVD), and atherosclerosis of medium- and large-vessels10. This comorbidity of neuropathy and PVD puts
patients at increased risk for chronic foot ulceration with impaired surface wound healing, which is seen in
25% of diabetic patients12. These ulcers often go unnoticed and become infected, which leads to increased
medical costs, limb amputation, or death12,13. Diabetes also causes microvascular disease due the
irreversible deposition of cross-linked advanced glycation end-product (AGE) proteins14. These AGE
https://rdw.rowan.edu/crjcsm/vol4/iss1/7
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proteins create space-occupying vessel obstructions, resulting in decreased perfusion, growth inhibition,
apoptosis, and ultimately fibrosis of small vessels, seen in diabetic retinopathy. Diabetic
hypoperfusion-induced ischemia and hyperglycemic oxidative stress also leads to increased organ
fibrosis15,16. Fibrosis is characterized by increased extracellular matrix collagen deposition and the
presence of myofibroblasts, which ultimately lead to loss of functional tissue and contraction17,18. Diabetic
complications resulting from fibrosis include nephropathy, cardiomyopathy, coronary heart disease, stroke,
nonalcoholic fatty liver disease, and pulmonary fibrosis.
Several in vivo mouse models have been used to investigate the pathophysiology of diabetes. The chemical
agent streptozotocin (STZ) has been widely used to induce a type 1 diabetic state19,20. STZ is a toxic
glucose analogue that enters pancreatic islet β-cells via Glut-2 transporter and increases reactive oxygen
and nitrogen species19,21. This results in cell death and prohibits the biosynthesis and release of insulin,
leading to sustained hyperglycemia19,22. STZ-induced diabetic rodents exhibit many hyperglycemic
complications, including delayed wound healing, allodynia, hyperalgesia, visual impairment, renal
toxicity, bradycardia, hypotension and cardiomyopathy23,24. However, its use to study fibrosis has been
limited due to the long time-course of at least six months before the overt manifestations of fibrotic
collagen depositions are apparent on histopathology25. Further, STZ-induced diabetes model needs to be
coupled with costly genetic deficiencies to recapitulate renal fibrosis, and it requires at least six months of
hyperglycemia to reproduce early signs of diabetic retinopathy, such as loss of retinal pericytes and
capillaries, thickening of the vascular basement membrane, vascular occlusion and increased vascular
permeability25−29.
Extracellular matrix depositions and the appearance of myofibroblasts are thought to be hallmarks of
fibrosis and wound healing across many tissues, including retinal, brain, renal, and lung samples30−35.
Alpha-Smooth Muscle Actin (α-SMA) is an intracellular protein expressed in these myofibroblasts that is
responsible for the contractility of these cells36. As such, α-SMA represents a key marker of the
myofibroblastic phenotype. Nonetheless, the pathogenesis of fibrosis and appearance of myofibroblasts is
complex, and α-SMA as a fibrotic marker has been inconsistent in pulmonary, renal and muscle
fibrosis37,38. These inconsistences could be attributed to differences in tissue properties, disease stages,
experimental models or varied etiologies of the fibrotic disease39,40.
The validation of methods and reliable markers to specifically detect early, quantifiable fibrotic changes
seen in the diabetic state is of fundamental importance for understanding the diabetic pathophysiology and
exploring earlier management options. Here, we investigated if we could detect early signs of internal
fibrosis in an STZ-induced diabetic mouse model by measuring α-SMA expression in various organs by
flow cytometry. Flow cytometry offers unique advantages over tissue histology alone, including quick
Published by Rowan Digital Works, 2022
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individual cell analysis and cell sorting for further molecular studies. This method would be useful to
characterize molecular and cellular changes that precede histological manifestations of fibrosis and overt
disease burden seen in patients.

METHODS

This study was carried out in strict accordance with the recommendations in the Guide for the Care and
Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the
Institutional Animal Care and Use Committee (IACUC) of Rowan University School of Osteopathic
Medicine (Protocol Number: 2017-34). All surgery was performed under Isofluorane anesthesia, and all
efforts were made to minimize suffering.
Establishment of T1DM Model: C57BL/6J male mice (The Jackson laboratories, Bar Harbor, ME) were
split into normoglycemic control and hyperglycemic STZ-treated groups. At post-natal day 21 mice were
injected using a low-dose streptozotocin (STZ) induction protocol (Figure 1A, B). STZ was resuspended
in sodium-citrate buffer solution (pH 4.5) and injected within 10 min from preparation. Mice were injected
daily intraperitoneally with 50 mg/kg STZ after fasting for 4-6 hours. STZ-driven β-cell destruction may
cause severe hypoglycemia, which may be lethal. This was prevented using 10% sucrose solution for 48
hours immediately following STZ initiation19. Normoglycemic mice were injected with sodium-citrate
buffer only. Blood glucose has been shown to peak and remain stable at three days post-STZ treatment41.
Glycemia was checked after 5-10 days. Mice with glucose <250 mg/dL were re-injected. Hyperglycemia
was sustained for 8-10 weeks prior to wounding.
Glycemia measurement: Prior to measurement, mice were food-starved for 4 hours with water ad libitum.
A scalpel was used to pierce the tail and collect a drop of blood for glucose measurement using a Bayer
Contour glucometer.
Wound healing model: At 8-10 weeks post-treatment, hyperglycemic and normoglycemic mice were
anesthetized with isoflurane, the mouse dorsum was shaved, skin was disinfected, and two full-thickness
excisional wounds were made in the anterior dorsal skin on each side of the midline with a 6 mm punch
biopsy tool (Tru-Punch Sterile Disposable Biopsy Punches, Sklar Surgical Instruments, West Chester, PA).
Silicon rings were custom made in house from a silicon pad (1/16 inch thick silicon sheet, Grainger, Inc.)
using a 8 mm punch biopsy (Tru-Punch Sterile Disposable Biopsy Punches, Sklar Surgical Instruments,
West Chester, PA) and manual cutting. This was applied with surgical glue and sutures to prevent the
panniculus carnosum from closing the wound via contraction42−45 (Figure 2A). Wound dressing (3MTM
TegadermTM) was applied after lubricating the wound with aqueous bacteriostatic gel (Surgilub, HR
Pharmaceuticals, Inc., York, PA). Mice were monitored daily for 3 days for vitals and to ensure no
https://rdw.rowan.edu/crjcsm/vol4/iss1/7
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post-wound infections. Wounds were imaged and measured with digital calipers at 24 hours and for 3
times a week for 2 weeks.
Wound Histology: Surface wounds and matching unwounded epithelial regions from both normoglycemic
and hyperglycemic mice were excised and stained for Hematoxylin and Eosin (H&E) and Masson
trichrome using standard protocol (Figure 2 C, D). Samples were imaged at 50x with Leica DMi8 and
DFC 7000C. Epidermal and dermal wound depth was measured with ImageJ at the maximal perpendicular
height from the basement membrane. Fibrosis was quantified based on the percent of collagen present
across the central 2.5 mm of the wound site, as seen on trichrome stain. Collagen was quantified using the
“Colour Deconvolution” plug-in as previously described by Chen et al46 (Figure 2E).
Tissue dissociation and flow cytometry: Whole organs, including brain, retinas, heart, lung, liver, kidney,
pancreas, and peritoneal fat were collected from 8 normoglycemic and 8 hyperglycemic mice at the end of
the experiment and dissociated using gentleMACSTM Dissociator (Miltenyi Biotec) (Figure 3A). Tissues
were cut in small pieces with a scalpel and dissociated with tissue-specific programs of gentleMACS. 8
mice were used to generate 2 retina samples by pooling the retinas from 4 mice in each sample, for a total
n=2 for both diabetic and non-diabetic samples. All other organs were analyzed individually, for a total
n=4-8. Intracellular staining for alpha-smooth muscle actin (α-SMA) was performed on single cell
suspensions. First, cells were fixed and permeabilized using Transcription Factor Buffer Set (BD
Biosciences, Jose, CA). Then cells were incubated with 2% mouse normal sera to block non-specific
binding, followed by incubation with Alexa 488 conjugated anti-human α-SMA antibodies (Invitrogen,
clone 1A4). Matching isotype control was used to determine background fluorescence level. Cells were
analyzed by Flow cytometry to quantify α-SMA protein levels using S1000EX Flow cytometer
(Stratedigm, San Jose, CA). Data were analyzed using CellCapture software (Stratedigm).

RESULTS

The T1DM model yielded highly efficient pathogenesis with 100% survival following STZ treatment with
sucrose supplement. 90% of mice had sustained hyperglycemia (>250 mg/dL) at two weeks following one
serial 5-day low-dose STZ treatment. The remaining 10% were given a second serial 5-day low-dose STZ
treatment, after which all STZ-treated mice demonstrated sustained hyperglycemia (>250 mg/dL) (Figure
1C). Control mice injected with sodium-citrate buffer demonstrated 100% survival and normoglycemia
(<150 mg/dL). Diabetic mice also demonstrated characteristic weight loss over the study period (Figure
1D). Diabetic mice demonstrated polyuria requiring more frequent cage changes (data not shown), as
previously reported47,48.
Full thickness excisional wounds with splints were photographed and measured for two weeks. A
Published by Rowan Digital Works, 2022
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representative image demonstrates the delay in wound healing seen grossly in diabetic mice, with
measurements confirming delayed wound healing (Figure 2A, B). H&E histology stain demonstrated
morphological differences in cellular architecture between unwounded and wounded tissues (Figure 2C).
Unwounded tissue samples demonstrated no significant difference in dermal height in diabetic tissue
compared to normoglycemic tissues, although unwounded diabetic tissues demonstrated thinner dermal
height than all other samples (Figure 2F). Epidermal height for both groups was significantly increased
post-injury (Figure 2G, p<0.0001). Diabetic wound tissues showed a larger increase in epidermal height
than normoglycemic wound tissue (mean fold-change normoglycemic = 2.3; mean fold-change diabetic =
6.0). Trichrome analysis showed similar baseline collagen content in diabetic and normoglycemic
unwounded tissues (Figure 2H). Post-injury, diabetic wounds demonstrated significantly impaired collagen
deposition relative to normoglycemic controls (p<0.05).
Cell flow cytometry analysis has shown a significant increase in the percentage of α-SMA-positive cells
only in brain and retinal tissues of diabetic mice compared to normoglycemic ones (Figure 3B). Although
the fraction of α-SMA-positive cells did not increase in kidney and heart tissues of diabetic mice, we
observed an increase in cellular levels of α-SMA expression, as demonstrated by increased α-SMA mean
fluorescent intensity of these samples (data not shown). No difference was observed between
normoglycemic and diabetic lung, liver, pancreas, skin, or peritoneal fat in numbers of α-SMA-positive
cells or α-SMA mean fluorescent intensity.

DISCUSSION

Given the high prevalence of diabetes and its complications, we reproduced a low-dose STZ-induced
T1DM mouse model with didactic and research purposes. STZ-induced diabetes is a valuable method to
study hyperglycemic complications seen in both T1DM and T2DM, including peripheral vascular disease
and wound healing delay23,24. In the past, this model has presented cumbersome, costly, and
time-intensive limitations for the study of hyperglycemic complications including pulmonary fibrosis,
cardiomyopathy, retinopathy, and kidney fibrosis25,26,49,50. Here, we investigated if we could detect early
signs of fibrosis by quantifying the number of α-SMA-positive cells across organs using flow cytometry,
paired with complementary histologic analysis of surface wounds to corroborate our diabetic state.
We combined several known protocols to achieve the highest rate of diabetes induction. We successfully
established a T1DM mouse model with 100% efficiency and survival, confirmed by sustained
hyperglycemia, polyuria, weight loss and delayed wound closure rates compared to normoglycemic
controls (Figures 1C, 1D and 2B). This is consistent with the disease manifestations seen in diabetic
patients12.
https://rdw.rowan.edu/crjcsm/vol4/iss1/7
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Histologic analysis demonstrated a greater increase in diabetic post-injury epidermal height than in
normoglycemic tissue, indicating greater inflammation. Unwounded dermal height is smaller in diabetic
mice than normoglycemic mice, but post-injury diabetic dermal height increased to match normoglycemic
dermal height. Post-injury collagen deposition was decreased in diabetic mice. This is consistent with
previous studies of the impaired re-epithelialization of diabetic wounds in both rat models and diabetic
patients, which found that hyperglycemic tissues have altered collagen and elastin deposition23,51,52. These
histologic findings further validate the diabetic state in our model system and offer a robust method for
tracking the architectural changes that take place on a cellular scale in the hyperglycemic state.
The cellular analysis using flow cytometry demonstrated increased number of α-SMA-positive cells in the
brain and eyes of diabetic mice (Figure 3B). α-SMA is a well-known marker of myofibroblasts, the cells
implicated in fibrosis30. Diabetes is known to cause macrovascular disease by direct hyperglycemic injury
to the vascular endothelium and by inhibition of nitric oxide, resulting in vasoconstriction, increased
intravascular inflammation, and atherosclerosis10. The increase of α-SMA in brain tissue may indicate
early atherosclerosis preceding diabetic stroke53. It is also possible this increase in α-SMA plays a role in
dementia pathogenesis, although the exact mechanism for the increased prevalence of dementia among
diabetic patients is unknown54,55.
Prior studies of STZ-induced hyperglycemia have confirmed retinopathy in mice after 24-64 weeks of
sustained hyperglycemia27−29. Here we found increased number of α-SMA-positive cells in brain and
retina tissues at 10-12 weeks after hyperglycemia onset. This suggests that pro-fibrotic α-SMA-positive
myofibroblasts precede the appearance of overt clinical signs. Our observation is consistent with a study
that identified elevated expression of N-cadherin, α-SMA, Snail, fibronectin and connective tissue growth
factor in retinal tissue purified from patients with proliferative diabetic retinopathy29. Our finding of
elevated α-SMA expression in diabetic retinal tissues is also consistent with the fact that microvascular
retinopathy is one of the earliest complications in young patients56. This finding is unlikely to simply be
the result of STZ toxicity to retinal ganglion cells, as similar levels of retinal fibrosis have been identified
across many diabetic animal model systems as well as in diabetic patient autopsies57,58.
We were not able to confirm elevated α-SMA expression in the rest of the analyzed organs. The short
diabetic disease state of 10-12 weeks at sustained hyperglycemia may be insufficient to lead to these
late-stage disease complications that are often seen decades into the disease in humans. Further, although
α-SMA has long been used as the standard marker for fibrosis, studies have shown that α-SMA-negative
lung and kidneys are able to manifest fibrosis by other means38,59. Certain tissues express higher levels of
alternate proteins during wound repair, such as Smad, N-cadherin, β-catenin, and Snail15,29,30,60. Another
possible explanation for this discrepancy is that α-SMA expression may only be present in tissues that are
Published by Rowan Digital Works, 2022
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actively expressing fibrotic components and laying down extracellular collagen and fibrin networks61.
After the fibrosis has taken place and collagen is laid down, α-SMA expression decreases and may not be
detectable by flow cytometry. It would be useful to investigate the histology of these internal organs to
visualize the extent of fibrosis.
Further analysis of organ-level diabetic fibrosis would benefit from the use of additional molecular
markers to account for the variety of fibrotic response in different tissues. Flow cytometry offers a
convenient method to assess the number of cells positive for a marker of interest such as α-SMA. Several
cell markers could be detected simultaneously to define a pre-fibrotic profile and cascade of molecular
events. For example, epithelial to mesenchymal transition (EMT) has been indicated as a process that can
generate myofibroblasts and has been implicated directly in fibrosis62. A parallel biopsy and histologic
analysis could offer complementary evidence of fibrosis and hyperglycemia-induced changes.
In summary, we successfully established the use of flow cytometry to detect early changes in the number
of α-SMA positive cells in brain and retina tissue of a T1DM murine model obtained with low-dose STZ
protocol. The STZ protocol is a well-known, robust and reliable method to induce diabetic hyperglycemia.
We have coupled it with flow cytometry to demonstrate the feasibility of quantitative measurements of the
number α-SMA-positive cells and observed changes in brain and retinal tissues. This cellular analysis is
representative of increased vascular fibrosis in hyperglycemic mice central nervous system tissues,
detectable as early as 10-12 weeks after hyperglycemia onset. Flow cytometry is a fast, reproducible, and
reliable quantitative method that could be used to study organ fibrosis in this and other diabetic models.
The quantification of cell markers involved in fibrosis could be used to investigate early events preceding
diabetic retinopathy, stroke or dementia.
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Table 1 Enzyme mixture and gentleMACSTM Dissociator specifications for tissue processing.

Tissue
Brain

Enzyme (5 mL)
Trypsin EDTA

Media
DMEM High Glucose

Retina

Trypsin EDTA

DMEM High Glucose

Heart

0.15% Collagenase Type I & 0.4% BSA in
PBS
0.15% Collagenase Type I & 0.4% BSA in
PBS
0.15% Collagenase Type I & 0.4% BSA in
PBS
0.15% Collagenase Type I & 0.4% BSA in
PBS
Trypsin EDTA

DMEM High Glucose

DMEM High Glucose

0.1% Collagenase Type I & 0.4% BSA in
PBS

DMEM High Glucose/
M199

Lung
Liver
Kidney
Pancreas
Fat
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DMEM High Glucose

Time
15 minutes at 37
◦C
15 minutes at 37
◦C
30 min at 37 ◦C
30 minutes at 37
◦C

DMEM High Glucose
DMEM High Glucose

15 minutes at 37
◦C
1 hour at 37 ◦C
6-16 hours at 4
◦
C
1 hour at 37 ◦C
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Figure 1 Hyperglycemic wound healing murine model. (A) Schedule for STZ injections, blood glucose
monitoring, full thickness wound, healing, and termination. Histology slides and flow cytometry specimen were
prepared at termination. (B) STZ was used to induce hyperglycemic diabetic state (blood glucose >250 mg/dL), and
citrate buffer was injected to maintain normoglycemic control (blood glucose <250 mg/dL). STZ injections yielded
100% survival. 90% of STZ-treated mice demonstrated hyperglycemia after one treatment regimen, and 100%
demonstrated hyperglycemia after a second treatment regimen. (C) STZ-treated mice demonstrated sustained
hyperglycemia, confirmed prior to wounds (student’s t-test, p<0.0001, normoglycemic n=30; hyperglycemic n=40).
(D) STZ-treated mice demonstrated sustained weight loss, confirmed prior to wounds (student’s t-test, p<0.0001,
normoglycemic n=30; hyperglycemic n=40).
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Figure 2: Wound healing analysis of dorsal skinfold at control and wound sites. (A) Gross imaging of splinted
wounds at day 1 and 17 post-injury. (B) Gross measurement of wound closure over time demonstrates delayed closure
in hyperglycemic mice. Error bars indicate standard deviation. (C) H&E stain of normoglycemic (Ng) and
hyperglycemic (Hg) unwounded and wounded dorsal skin. (D) Masson-Trichrome stain of normoglycemic and
hyperglycemic unwounded and wounded dorsal skin. (E) ImageJ Color Deconvolution image processing of
normoglycemic G8-treated wound tissue Trichrome stain to isolate collagen stain. (F) Baseline dermal height was
decreased in unwounded hyperglycemic mice compared to normoglycemic controls, although not statistically
significant. Post-injury, no difference is seen in dermal height of normoglycemic and hyperglycemic tissue. Data was
analyzed using unpaired 2-tailed student t-test. Ng unwounded and wounded n=16; Hg unwounded and wounded
n=14. (G) Post-injury, epidermal height was significantly increased in both normoglycemic and hyperglycemic mice
(P<0.0001). The fold-increase of unwounded to wounded epidermal height was larger in hyperglycemic mice
(normoglycemic = 2.3, hyperglycemic = 6.0). Data was analyzed using unpaired 2-tail student t-test. Ng unwounded
and wounded n=16; Hg unwounded and wounded n=14. (H) Decreased collagen deposition was seen in
hyperglycemic wounds compared to unwounded normoglycemic tissue (P<0.05). Data was analyzed using unpaired
2-tail student t-test. Ng unwounded and wounded n=15; Hg unwounded and wounded n=14.
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Figure 3 Flow cytometry analysis of internal fibrosis.(A) Mice were dissected to isolate brain, heart, lung, liver,
kidney, pancreas, skin, peritoneal fat, and retinal tissue. Organs were digested using gentleMACSTM Dissociator at
the specifications listed in Table 1 to procure cell suspension. (B) Flow cytometry data analysis of normoglycemic
(Ng) and hyperglycemic (Hg) tissues revealed increased total of α-SMA-positive cells in hyperglycemic retinas and
brain (P<0.01) (unpaired 2-tail t-test). No difference was seen between normoglycemic and hyperglycemic lung,
liver, pancreas, skin, or peritoneal fat. N=4-8 as shown, retina n=2.
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